Temsirolimus treats lung cancer gene mutations

Lung cancer is one of the most common forms of cancer and remains the leading cause of cancer-related death in men and women worldwide. Based on histological differentiation, there are two main types of lung cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Temsirolimus has been reported to restore the sensitivity of lung cancer cell lines to cisplatin by blocking the translation of proteins involved in cisplatin resistance.

The cytostatic effect of temsirolimus has also been demonstrated through the introduction of temsirolimus as a molecularly targeted drug with the potential to inhibit tumor cell regeneration. However, pulmonary toxicity has been associated with mTOR inhibitors and many other drugs, including anticancer agents. Appropriate management of chemotherapy strategies and diagnosis of clinical pulmonary symptoms should be considered when using mTOR inhibitors. Research shows that in a mouse lung tumor model, a combination of low-dose chemotherapy and temsirolimus treatment was more effective than a dual chemotherapy regimen in inhibiting tumor growth. Furthermore, simultaneous administration of combination therapy is more effective than sequential administration of these drugs at higher doses. However, temsirolimus has not yet been approved for the treatment of lung cancer.

The original drug temsirolimus has not yet been marketed in China, and therefore cannot be included in domestic medical insurance. The original temsirolimus drug marketed overseas has a Turkish version and a European version. The ingredients of the two are basically the same. The price of each box of 30mg/1.2mL may be more than 10,000 yuan, and the price of 25mg/mL may be around 3,000 yuan per box (the price may fluctuate due to exchange rates). There is currently no generic version of temsirolimus available on the market. For more drug information and specific prices, please consult a medical consultant.